

16TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Wednesday, 27th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 12:30

3 external CPD credits

13:30 – 13:45 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Huvitz, Fred Hutch Cancer Center

13:45 – 14:15 **HER2 as a therapeutic target in HER2-normal breast cancer**

Prof. Sara Huvitz, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Head, Division of Hematology and Oncology, University of Washington

14:15 – 14:45 **Targeting Estrogen Receptor in breast cancer: old target, new drugs.**

Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston

14:45 – 15:15 **HER2+ GP2 vaccine and the FLAMINGO Phase III trial**

Mr. Snehal Patel, CEO, Greenwich Lifesciences

15:15 – 15:30 **Coffee break**

TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Huvitz, Fred Hutch Cancer Center

15:30 - 16:15 **Patient-derived models of breast cancer for drug discovery and precision medicine**

Dr. Alana Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

16:15 – 16:45 **TPD squared - Dual-Precision Targeted Protein Degradation for Oncology Therapeutics Discovery and Development**

Dr. James Palacino, Head of Research, Orum Therapeutics

KEYNOTE PRESENTATION

16:45 - 17:30 **Topic: CDK inhibitors and the NATALEE clinical trial**

Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology.

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

FOR ALL SOCIAL MEDIA PLEASE INCLUDE #TRANSONCXVI

16TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Thursday, 28th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30

6 external CPD credits

TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto

09:00 - 09:30 **Use of mice, immunologically tolerant to foreign reporter proteins for immunotherapy and TME studies**
Prof. Robert Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto

09:30 - 10:00 **Overcoming endothelial cell anergy for improvement of immunotherapy against cancer**
Prof. Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC

10:00 - 10:30 **Orally available RGD-mimetic and enhancement of immunotherapy efficacy**
Prof. Kairbaan Hodivala Dilke, Professor of Tumour Microenvironment, Queen Mary University of London, and Deputy Director of Barts Cancer Institute.

10:30 - 10:45 **Coffee break**

TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto

10:45 - 11:15 **Brain metastasis in the era of immunotherapy: implications for sequential immunotherapy-based combination therapy**
Prof. Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center

11:15 – 11:45 **Control of malignant properties by functionally and spatially distinct cancer-associated fibroblasts**
Prof. Kristian Pietras, Division of Translational Cancer Research, Lund University Cancer Centre

11:45 – 12:15 **Extracellular Vesicles in the Tumour Microenvironment**
Prof. Lorraine O'Driscoll, School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin

KEYNOTE PRESENTATION

12:15 – 13:00 **Normalizing the tumor microenvironment to improve immunotherapy of brain tumors: Emerging insights and strategies**
Prof. Rakesh Jain, National Medal of Science Awardee 2013, Andrew Werk Cook Professor of Tumor Biology, Massachusetts General Hospital, Harvard Medical School & Director E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital.

13:00 - 14:00 **Lunch**

TARGETING DIFFICULT TO DRUG GENES FOR CANCER THERAPY:

Session Chair – Prof Joe Duffy, St. Vincent's University Hospital/University College Dublin

14:00 - 14:30 **Targeting MYC: A Dual Effect on Both Cancer Cells and Tumor Microenvironment**
Prof. Michael J. Duffy, Clinical Research Centre, St. Vincent's University Hospital, Dublin.

14:30 – 15:00 **Biomarker driven development of Brigimadlin, a MDM2-p53 antagonist restoring p53 activity**
Dr. Michael Teufel, Exec Dir Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim

15:00 - 15:30 **Combination strategies to potentiate the impact of KRAS inhibitors**
Dr. Miriam Molina-Arcas, Oncogene Biology Laboratory, The Francis Crick Institute

15:30 - 15:45 **Coffee break**

NOVEL TARGETED THERAPIES: Session Chair – Prof. Denis Collins, Dublin City University

15:45 - 16:15 **Development of a novel therapeutic mAb and ADC for CLDN18.2**
Dr. Neil O'Brien, Adj Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA

16:15 - 16:45 **Selective Therapies for Metastatic Tumor Cells**
Prof. Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Harvard

16:45 - 17:15 **Evolving insights into biomarkers and treatment of hepatocellular carcinoma**
Prof. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.

17:15 – 17:45 **Development and characterization of an anti-Claudin-6 (CLDN6) ADC for the treatment of CLDN6 positive cancer**
Dr. Martina McDermott, Adj Assoc Prof, Dept of Medicine, Division of Hematology/Oncology, UCLA

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.

16TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Friday 29th September 2023, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30

4 external CPD credits

CANCER IMMUNOTHERAPY I – EXPLOITING IMMUNE CELLS: Session Chair – Prof. Mario Sznol, Yale

- 09:00 - 09:30 **DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity**
Dr. Michael Dougan, Massachusetts General Hospital, Harvard Medical School
- 09:30 - 10:00 **Novel Biomarker Discovery for NX-1607: Clinical Insights into a First-in-Class Oral CBL-B Inhibitor for Advanced Malignancies**
Dr. Sarah Whelan, Associate Director, Translational Medicine, Nurix Therapeutics
- 10:00 - 10:30 **ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors**
Prof. Dr. med Oliver Ebert, Senior Director, Head of Clinical Development, Immatix
- 10:30 – 11:00 **Cancer cell metabolomics and immunotherapy resistance**
Prof. Ken O' Bryne, Professor of Medical Oncology, Queensland University of Technology
- 11:00 – 11:15 *Coffee break*

CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale

- 11:15– 11:45 **Cis-targeting of IL-2 and IL-21 cytokines to CD8+ T cells to improve immunotherapies for cancer**
Dr. Ivana Djuretic, Chief Scientific Officer, Asher Biotherapeutics
- 11:45 – 12:15 **Development of XTX301, a bioengineered masked, tumor-activated IL-12: unleashing the potent cytokine in the tumor microenvironment**
Dr. Katarina Luptakova, MD, Senior Vice President, Medical, Xilio Therapeutics
- 12:15 - 12:45 **New Strategies in Immuno-Oncology: Tumor-directed Oncolytic Immunotherapy (TOI)**
Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune
- 12:45 – 13:00 **Cancer Immunotherapy Panel Discussion**
- 13:00 – 14:00 *Lunch*

NOVEL TARGETED DRUGS & BIOMARKERS: Session Chair - Prof William Gallagher, University College Dublin

- 14:00 - 14:30 **Cancer as a combinatorial challenge**
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
- 14:30 – 15:00 **Targeting mediator kinases in prostate and breast cancers**
Prof. Igor Roninson, CSO, Senex Biotechnology & Prof. Eugenia Broude, University of South Carolina
- 15:00 - 15:30 **The role of MRD detection and quantitation in solid tumors**
Dr. Minetta Liu, Chief Medical Officer, Natera
- 15:30– 15:45 *Coffee break*

NOVEL TARGETED DRUGS & BIOMARKERS II: Session Chair - Prof John Crown, St Vincent's Hospital

- 15:45 – 16:15 **Understanding TIL therapy for metastatic melanoma**
Prof. John Haanen, Medical Oncology Dept. Netherlands Cancer Institute
- 16:15 – 16:45 **A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)**
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine
- 16:45 – 17:15 **Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: post adjuvant PD-1 analysis**
Prof. John Crown, Consultant Medical Oncologist, St Vincent's Hospital, Dublin; Professor of Oncology, University College Dublin; Thomas Baldwin Chair of Translational Oncology, Dublin City University

The organisation of this meeting has been funded by third party sponsors, however, none of these sponsors have had any influence over the educational/scientific content of presentations or the agenda of the meeting.